Efficacy and Safety of Sofosbuvir and Ribavirin in an Italian Cohort of HCV Genotype 2 Elderly Cirrhotic Patients

Objective: Sofosbuvir and ribavirin represented until recently the standard of care in hepatitis C virus genotype 2 cirrhotic patients. In registration trials, 12-16 week durations were associated with 90% sustained virological responses, although not confirmed by real-life studies. In Italy, variou...

Descripción completa

Detalles Bibliográficos
Autores principales: Smirne, Carlo, Carbone, Roberto, Colletta, Cosimo, Scivetti, Paolo, Sainaghi, Pier Paolo, Elena, Grossini, Pirisi, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Atatürk University School of Medicine 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634894/
https://www.ncbi.nlm.nih.gov/pubmed/35703517
http://dx.doi.org/10.5152/eurasianjmed.2022.20421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634894/
https://www.ncbi.nlm.nih.gov/pubmed/35703517
http://dx.doi.org/10.5152/eurasianjmed.2022.20421

Ejemplares similares